The Anticoagulation Quality Improvement Analyzer (AQuIA) is a VeriSign Code Signing Certificate software to identify gaps in care between recognized anticoagulation guidelines and practice patterns in a health-system based on retrospective pharmacy and medical claims analysis. Benchmark data from nationally representative commercial, Medicare and Medicaid referenced datasets are displayed alongside plan specific data as a means to quickly compare plan demographics, anticoagulation therapy, and resource utilization. In addition to customized population level data, this analyzer has the functionality to provide patient and provider level measures to identify opportunities to develop interventions that promote quality improvement, increased treatment of at risk patients, and potentially decrease health care resource utilization. The user-friendly interface will also provide additional descriptive and actionable measures at the patient, provider and health-plan levels that are potentially meaningful to pharmacy, medical and quality improvement directors.

The Anticoagulation Quality Improvement Analyzer (AQuIA) Integrated Module is a Symantec Code Signing Certificate software to identify gaps in care between recognized anticoagulation guidelines and practice patterns in a population. The tool is designed to conduct retrospective analyses of claims (medical and pharmacy) and/or electronic health record (EHR) data. The purpose of the tool is to assist your organization’s evaluation of current practice patterns, resource utilization, and quality measure attainment overtime. In addition to customized population level data, this analyzer has the functionality to provide patient and provider level measures to identify opportunities to develop interventions that promote quality improvement, increased treatment of at risk patients, and potentially decrease health care resource utilization. The user-friendly interface will also provide additional descriptive and actionable measures at the patient, provider and organization levels that are potentially meaningful to pharmacy, medical and quality improvement directors.

The Quality Population Analyzer Tool for Healthcare systems (QualityPATH) is a Symantec Code Signing Certificate software that allows your organization to review type 2 diabetes (T2DM) data based on retrospective medication, medical, and/or laboratory data analysis. Additionally, two new modules have been added to QualityPATH – the Diabetic Kidney Disease (DKD) Prevalence Module and the Cardiovascular Disease (CVD) Risk Module. These modules provide insights on micro- and macrovascular complications that are major causes of morbidity and mortality in T2DM patients. 

QualityPATH can process claims (medical and pharmacy) and/or electronic health record (EHR) data. In the T2DM module, reference data from an integrated claims-EHR database are displayed alongside your organization’s data as a means to quickly compare demographics, antihyperglycemic agent utilization, resource utilization, and adherence to quality measures. In addition to providing customized population-level data, the analyzer has the functionality to provide patient- and provider-level reports.

The Assessment for Quality Improvement and Risk Evaluation program assists customers in identifying opportunities to improve treatment for patients with schizophrenia. Using actual client data, this tool provides a quick look into adherence rates, hospitalizations, and likelihood of future non-adherence and hospitalizations.

More information on the Assessment for Quality Improvement and Risk Evaluation (QI-RE) Tool [PDF] and QI-RE Data Preparation Guide [PDF].

The Health Outcomes Research Tutorial Tool for Type 2 diabetes (HORTT T2DM) is a web-based eLearning application developed to enhance your understanding of clinical research in T2DM and to provide important points to consider when interpreting study design, endpoints, and methodologies. This application provides a didactic overview of three chapters: Chapter 1 discusses study design in T2DM; Chapter 2 discusses common endpoints used in clinical studies of T2DM; and lastly Chapter 3 discusses some methodological considerations in clinical studies. The module concludes with a checklist, which can be used as a reference while evaluating published clinical studies.

The Autism Behavior Inventory (ABI), is a 62-item caregiver report developed for assessing changes in core and associated symptoms of autism spectrum disorder (ASD). It is designed to capture the behavior of individuals with ASD, aged three to adult, that have occurred over the past week. It is a web or paper based tool which assesses behavior across five domains (two ASD core domains: social communication, restrictive and repetitive behaviors; three associated domains: mental health, self-regulation, and challenging behavior). The paper version of the ABI is available for download and use, subject to conditions.

The Autism Behavior Inventory Short Form (ABI-S), is a 24-item caregiver report developed for assessing changes in core and associated symptoms of autism spectrum disorder (ASD). It is designed to capture the behavior of individuals with ASD, aged three to adult, that have occurred over the past week. It is a web or paper based tool which assesses behavior across five domains (two ASD core domains: social communication, restrictive and repetitive behaviors; three associated domains: mental health, self-regulation, and challenging behavior). The ABI-S takes less time to complete than the full ABI and may be used for more frequent assessments. The paper version of the ABI-S is available for download and use, subject to conditions.

The Schizophrenia Health Outcomes Research Tutorial Tool (SHORTT) is a web-based eLearning application developed to enhance your understanding of clinical research in schizophrenia and to provide important points to consider when interpreting study design, endpoints, and methodologies. This application provides a didactic overview of three chapters: Chapter 1 discusses study design in schizophrenia; Chapter 2 discusses common endpoints used in clinical studies of schizophrenia; and lastly Chapter 3  discusses some methodological considerations in clinical studies. The module concludes with a checklist, which can be used as a reference while evaluating published clinical studies.